Developer docs
API playgroundTry for free, no card

Search company profiles

Mobia Medical

Full company profile

uuid0000gae

Namestring
Mobia Medical
Legal namestring
Mobia Medical, Inc.
Websiteurl
mobia.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Mobia Medical, Inc. (formerly MicroTransponder, Inc.) is a publicly traded medical device company (Nasdaq: MOBI) headquartered in Austin, Texas with operations in Fridley, Minnesota and Newport Beach, California. Founded in 2007, the company develops and commercializes the Vivistim® Paired VNS™ System, an FDA-approved implantable neurostimulation device that pairs targeted vagus nerve stimulation with functional rehabilitation therapy to promote neuroplasticity and improve upper extremity motor function in chronic ischemic stroke survivors with moderate to severe impairment. The platform is grounded in NIH-funded research by co-founder and Chief Scientific Officer Navzer Engineer (MD, PhD), published in Nature and The Lancet, and is protected by a portfolio of 25+ issued US patents with foreign counterparts.

The company monetizes Vivistim through hardware sales of the implantable neurostimulation system, supplemented by ongoing rehabilitation therapy delivery at US stroke centers and therapy sites. Pricing is reimbursement-driven via Medicare (with a positive Medicare payment change announced in November 2025) and commercial insurance with prior authorization; device pricing is not publicly disclosed. Revenue reached $32 million on a trailing-twelve-month basis (as of mid-2026), representing 105% year-over-year growth, although the company remains unprofitable as it scales. The go-to-market is enterprise field sales-led, with a dedicated US team of Territory Managers, Clinical Education Managers, Therapy Development Specialists, and Patient Engagement Managers supported by an inside sales function handling patient intake, prior authorizations, and appeals. A dedicated patient-facing website (vivistim.com) and an "Am I a Candidate?" pre-screening tool capture and qualify consumer demand.

Mobia maintains a portfolio of sub-brands including Vivistim, Vivistim Therapy, Paired VNS, and the adjacent Serenity brand for tinnitus neurostimulation. The company completed its Nasdaq IPO in May 2026, raising approximately $150 million in gross proceeds, and is led by President and CEO Richard Foust, a former Abbott and Guidant commercial leader, with board oversight from Chairman Dana G. Mead, Jr. and institutional investors including U.S. Venture Partners, Osage University Partners, Longitude Capital, and Action Potential Venture Capital.

Short descriptiontext

Mobia Medical is a publicly traded medical device company that develops and commercializes the Vivistim Paired VNS System, the first and only FDA-approved implantable neurostimulation therapy for chronic ischemic stroke survivors with moderate to severe upper extremity impairment, sold to US stroke centers and reimbursed via Medicare and commercial insurance.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurostimulation medical devices, stroke rehabilitation therapy, vagus nerve stimulation, implantable medical devices, chronic stroke recovery
Industry2 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAIAG
Stroke & Vascular Neurology
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurostimulation Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Vivistim System Hardware Sales
TypeHardware Sales
Description

Commercial-stage medical device revenue generated through sales of the FDA-approved Vivistim® Paired VNS™ implantable neurostimulator for chronic ischemic stroke rehabilitation. Reached $32 million in trailing-twelve-month revenue with 105% year-over-year growth. Revenue mix is one-time implantable device plus ongoing rehabilitation therapy delivery; covered by Medicare/insurance reimbursement (positive Medicare payment change announced November 2025).

ca.investing.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain
Pricing details1 tier
1Implantable medical device pricing, quote-based / not publicly disclosed
ModelOther
Notes

Pricing for the Vivistim® Paired VNS™ System is not publicly listed. Reimbursed via Medicare (positive Medicare payment change announced November 25, 2025) and commercial insurance with prior authorization. Patient assistance available for costs associated with the Vivistim Paired VNS System placement procedure and rehabilitation therapy for chronic ischemic stroke patients meeting eligibility requirements.

cnbc.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Vivistim
Description

Vivistim® Paired VNS™ System and Vivistim Therapy™ — implantable neurostimulation system and related components for treatment of stroke survivors.

mobia.com
+3 more records
Core offering1 text field

Mobia Medical develops and commercializes the Vivistim® Paired VNS™ System, an FDA-approved implantable neurostimulation device that delivers targeted vagus nerve stimulation paired with rehabilitation therapy to promote neuroplasticity and improve upper extremity motor function in chronic ischemic stroke survivors with moderate to severe arm impairment. The company sells the device plus associated clinical support services to US stroke centers, therapy clinics, and implanting physicians, reimbursed primarily through Medicare and commercial insurance.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Mobia Medical offers a single unified commercial-stage medical device franchise centered on the Vivistim® Paired VNS™ System and the associated Vivistim Therapy™ clinical protocol, both aimed at chronic ischemic stroke recovery. The implantable Vivistim System is supported by the Model 1001 vagus nerve lead as a hardware component. In parallel, the company maintains the Serenity® neurostimulation brand for the adjacent tinnitus indication. The current portfolio reflects Mobia Medical's evolution from MicroTransponder and the FDA approval of Vivistim as the first and only clinically validated solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairment.

Product and service2 records
1Vivistim® Paired VNS™ System
CategoryImplantable Neurostimulation Device
Description

An FDA-approved implantable neurostimulation device that delivers targeted vagus nerve stimulation paired with rehabilitation therapy to promote neuroplasticity and improve upper extremity motor function in chronic ischemic stroke survivors with moderate to severe arm impairment. Sold to US stroke centers, hospitals, certified therapy clinics, and implanting physicians.

2Vivistim Therapy™
CategoryClinical Therapy Protocol
Description

The clinical therapy protocol combining targeted vagus nerve stimulation delivered through the Vivistim System with structured functional exercises during rehabilitation to enable lasting improvements in motor pathways for chronic stroke recovery. Delivered at certified US stroke centers and therapy clinics.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-01-16
Description

Mobia Medical joined the Innovators' Network of the American Heart Association's Center for Health Technology & Innovation and its American Stroke Association division (announced January 16, 2026). The affiliation reflects Mobia's commitment to advancing responsible, evidence-based innovation in cardiovascular and stroke care and supports broader dialogue around recovery standards and patient outcomes.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-06-06
Description

Selected as one of 61 startups for MedTech Innovator's 2023 global medtech accelerator cohort (June 2023), gaining access to mentorship, competitions, funding opportunities, and industry exposure.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Inspire Medical Systems sells an implantable hypoglossal nerve stimulation system for obstructive sleep apnea, sharing Mobia's business model of an FDA-approved implantable neurostim device sold through a US specialty field-sales force to clinicians and reimbursed by Medicare and commercial payers.

2Axonics
TypeDirect peer
Description

Axonics (acquired by Boston Scientific in 2024) marketed rechargeable sacral neuromodulation implants for urinary and fecal dysfunction, an almost identical playbook to Vivistim — small implantable neurostim device, direct-to-specialist US field sales, and Medicare/commercial reimbursement dynamics in a chronic-condition population.

TypeDirect peer
Description

LivaNova (formerly Cyberonics) commercializes the original implantable vagus nerve stimulation (VNS) therapy, historically for drug-resistant epilepsy and treatment-resistant depression; it is the closest direct mechanism competitor to Vivistim's paired VNS platform and provides a benchmark for VNS category economics.

TypeDirect peer
Description

CVRx sells the Barostim neo system, an implantable neuromodulation device for heart failure and resistant hypertension; it mirrors Mobia's playbook of an FDA-approved implantable neurostim treating a chronic-condition population via a US specialty sales force with Medicare-dependent economics.

TypeDirect peer
Description

Nevro markets the HFX 10 kHz spinal cord stimulation system for chronic pain, another implantable neuromodulation franchise commercialized through a US physician-specialist field force with payer-reimbursement-driven unit economics — directly comparable to Mobia's commercial motion.

TypeEmerging player
Description

ElectroCore develops non-invasive vagus nerve stimulation (nVNS) via surface stimulation of the cervical vagus nerve for headache, epilepsy and other indications; it targets the same VNS mechanism as Vivistim but with a non-implantable delivery model, representing a potential adjacent or substitutive competitor for chronic neurological conditions.

TypeBroad incumbent
Description

Medtronic operates the world's broadest neuromodulation portfolio (Activa DBS, InterStim sacral neuromodulation, Intellis SCS, Percept PC) and serves as a large-incumbent reference point for how a multi-indication neurostim franchise is commercialized and scaled; competes indirectly via its VNS-adjacent DBS and emerging neuro-recovery research programs.

TypeBroad incumbent
Description

Abbott's Neuromodulation business includes the Proclaim DRG and Infinity DBS systems, positioning it as a broad incumbent across multiple implantable neurostim indications; relevant to Mobia as a potential acquirer or competitor leveraging shared hospital call points and similar reimbursement infrastructure.

TypeBroad incumbent
Description

Boston Scientific operates Vercise deep brain stimulation systems and acquired Axonics in 2024 to enter sacral neuromodulation, making it a broad incumbent in implantable neurostim with overlapping commercial channels and an active acquirer in the space (Mobia's leadership has multiple Boston Scientific alumni).

TypeOthers
Description

Penumbra is a neurovascular company whose stroke-thrombectomy franchise (and Lightning/Indigo product lines) is sold into the same US comprehensive stroke centers that are Mobia's Vivistim customers; it is not a direct competitor in chronic stroke recovery but shares the call point and is a relevant comp for stroke-care medtech economics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mobia Medical

Neurostimulation Medical Devicesmobia.com

Mobia Medical is a publicly traded medical device company that develops and commercializes the Vivistim Paired VNS System, the first and only FDA-approved implantable neurostimulation therapy for chronic ischemic stroke survivors with moderate to severe upper extremity impairment, sold to US stroke centers and reimbursed via Medicare and commercial insurance.

What Mobia Medical does

Mobia Medical, Inc. (formerly MicroTransponder, Inc.) is a publicly traded medical device company (Nasdaq: MOBI) headquartered in Austin, Texas with operations in Fridley, Minnesota and Newport Beach, California. Founded in 2007, the company develops and commercializes the Vivistim® Paired VNS™ System, an FDA-approved implantable neurostimulation device that pairs targeted vagus nerve stimulation with functional rehabilitation therapy to promote neuroplasticity and improve upper extremity motor function in chronic ischemic stroke survivors with moderate to severe impairment. The platform is grounded in NIH-funded research by co-founder and Chief Scientific Officer Navzer Engineer (MD, PhD), published in Nature and The Lancet, and is protected by a portfolio of 25+ issued US patents with foreign counterparts.

The company monetizes Vivistim through hardware sales of the implantable neurostimulation system, supplemented by ongoing rehabilitation therapy delivery at US stroke centers and therapy sites. Pricing is reimbursement-driven via Medicare (with a positive Medicare payment change announced in November 2025) and commercial insurance with prior authorization; device pricing is not publicly disclosed. Revenue reached $32 million on a trailing-twelve-month basis (as of mid-2026), representing 105% year-over-year growth, although the company remains unprofitable as it scales. The go-to-market is enterprise field sales-led, with a dedicated US team of Territory Managers, Clinical Education Managers, Therapy Development Specialists, and Patient Engagement Managers supported by an inside sales function handling patient intake, prior authorizations, and appeals. A dedicated patient-facing website (vivistim.com) and an "Am I a Candidate?" pre-screening tool capture and qualify consumer demand.

Mobia maintains a portfolio of sub-brands including Vivistim, Vivistim Therapy, Paired VNS, and the adjacent Serenity brand for tinnitus neurostimulation. The company completed its Nasdaq IPO in May 2026, raising approximately $150 million in gross proceeds, and is led by President and CEO Richard Foust, a former Abbott and Guidant commercial leader, with board oversight from Chairman Dana G. Mead, Jr. and institutional investors including U.S. Venture Partners, Osage University Partners, Longitude Capital, and Action Potential Venture Capital.

Mobia Medical firmographics

Firmographics
Name
Mobia Medical
Legal name
Mobia Medical, Inc.
Website
https://mobia.com
Company type
Public
Founded year
2007
Operating status
Ipo
Headcount range
51–100 employees
Short description
Mobia Medical is a publicly traded medical device company that develops and commercializes the Vivistim Paired VNS System, the first and only FDA-approved implantable neurostimulation therapy for chronic ischemic stroke survivors with moderate to severe upper extremity impairment, sold to US stroke centers and reimbursed via Medicare and commercial insurance.
Ownership category
akta.pro rank

Mobia Medical industry classification

Industry
Product category
Neurostimulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAIAG
Stroke & Vascular Neurology

Keywords

  • Neurostimulation medical devices
  • Stroke rehabilitation therapy
  • Vagus nerve stimulation
  • Implantable medical devices
  • Chronic stroke recovery

Where Mobia Medical is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Mobia Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain

Revenue model

  1. Vivistim System Hardware Sales: Commercial-stage medical device revenue generated through sales of the FDA-approved Vivistim® Paired VNS™ implantable neurostimulator for chronic ischemic stroke rehabilitation. Reached $32 million in trailing-twelve-month revenue with 105% year-over-year growth. Revenue mix is one-time implantable device plus ongoing rehabilitation therapy delivery; covered by Medicare/insurance reimbursement (positive Medicare payment change announced November 2025).

Pricing tiers

ModelBillingPrice
Other—Implantable medical device pricing, quote-based / not publicly disclosed

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Mobia Medical product offering

Product offering

Core offering

Mobia Medical develops and commercializes the Vivistim® Paired VNS™ System, an FDA-approved implantable neurostimulation device that delivers targeted vagus nerve stimulation paired with rehabilitation therapy to promote neuroplasticity and improve upper extremity motor function in chronic ischemic stroke survivors with moderate to severe arm impairment. The company sells the device plus associated clinical support services to US stroke centers, therapy clinics, and implanting physicians, reimbursed primarily through Medicare and commercial insurance.

Product overview

Mobia Medical offers a single unified commercial-stage medical device franchise centered on the Vivistim® Paired VNS™ System and the associated Vivistim Therapy™ clinical protocol, both aimed at chronic ischemic stroke recovery. The implantable Vivistim System is supported by the Model 1001 vagus nerve lead as a hardware component. In parallel, the company maintains the Serenity® neurostimulation brand for the adjacent tinnitus indication. The current portfolio reflects Mobia Medical's evolution from MicroTransponder and the FDA approval of Vivistim as the first and only clinically validated solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairment.

Differentiator

Problem solved

Functional benefit

Brands

  • Vivistim: Vivistim® Paired VNS™ System and Vivistim Therapy™ — implantable neurostimulation system and related components for treatment of stroke survivors.
  • Serenity
  • Vivistim Therapy
  • Paired VNS

Products and services

  • Vivistim® Paired VNS™ System An FDA-approved implantable neurostimulation device that delivers targeted vagus nerve stimulation paired with rehabilitation therapy to promote neuroplasticity and improve upper extremity motor function in chronic ischemic stroke survivors with moderate to severe arm impairment. Sold to US stroke centers, hospitals, certified therapy clinics, and implanting physicians.
  • Vivistim Therapy™ The clinical therapy protocol combining targeted vagus nerve stimulation delivered through the Vivistim System with structured functional exercises during rehabilitation to enable lasting improvements in motor pathways for chronic stroke recovery. Delivered at certified US stroke centers and therapy clinics.

Companies that use Mobia Medical

Customer profile

Segments4 records

Ideal customer profiles3 records

Mobia Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Mobia Medical partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • American Heart Association Center for Health Technology & Innovation (Innovators' Network)coreGTM or Marketing Partner · 16 January 2026Mobia Medical joined the Innovators' Network of the American Heart Association's Center for Health Technology & Innovation and its American Stroke Association division (announced January 16, 2026). The affiliation reflects Mobia's commitment to advancing responsible, evidence-based innovation in cardiovascular and stroke care and supports broader dialogue around recovery standards and patient outcomes.
  • MedTech InnovatorminorStrategic or Co-development Partner · 6 June 2023Selected as one of 61 startups for MedTech Innovator's 2023 global medtech accelerator cohort (June 2023), gaining access to mentorship, competitions, funding opportunities, and industry exposure.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Mobia Medical competitors and assessment

Company assessment

Direct peers

  • Inspire Medical Systems: Inspire Medical Systems sells an implantable hypoglossal nerve stimulation system for obstructive sleep apnea, sharing Mobia's business model of an FDA-approved implantable neurostim device sold through a US specialty field-sales force to clinicians and reimbursed by Medicare and commercial payers.
  • Axonics: Axonics (acquired by Boston Scientific in 2024) marketed rechargeable sacral neuromodulation implants for urinary and fecal dysfunction, an almost identical playbook to Vivistim — small implantable neurostim device, direct-to-specialist US field sales, and Medicare/commercial reimbursement dynamics in a chronic-condition population.
  • LivaNova: LivaNova (formerly Cyberonics) commercializes the original implantable vagus nerve stimulation (VNS) therapy, historically for drug-resistant epilepsy and treatment-resistant depression; it is the closest direct mechanism competitor to Vivistim's paired VNS platform and provides a benchmark for VNS category economics.
  • CVRx: CVRx sells the Barostim neo system, an implantable neuromodulation device for heart failure and resistant hypertension; it mirrors Mobia's playbook of an FDA-approved implantable neurostim treating a chronic-condition population via a US specialty sales force with Medicare-dependent economics.
  • Nevro: Nevro markets the HFX 10 kHz spinal cord stimulation system for chronic pain, another implantable neuromodulation franchise commercialized through a US physician-specialist field force with payer-reimbursement-driven unit economics — directly comparable to Mobia's commercial motion.

Emerging players

  • ElectroCore: ElectroCore develops non-invasive vagus nerve stimulation (nVNS) via surface stimulation of the cervical vagus nerve for headache, epilepsy and other indications; it targets the same VNS mechanism as Vivistim but with a non-implantable delivery model, representing a potential adjacent or substitutive competitor for chronic neurological conditions.

Broad incumbents

  • Medtronic: Medtronic operates the world's broadest neuromodulation portfolio (Activa DBS, InterStim sacral neuromodulation, Intellis SCS, Percept PC) and serves as a large-incumbent reference point for how a multi-indication neurostim franchise is commercialized and scaled; competes indirectly via its VNS-adjacent DBS and emerging neuro-recovery research programs.
  • Abbott: Abbott's Neuromodulation business includes the Proclaim DRG and Infinity DBS systems, positioning it as a broad incumbent across multiple implantable neurostim indications; relevant to Mobia as a potential acquirer or competitor leveraging shared hospital call points and similar reimbursement infrastructure.
  • Boston Scientific: Boston Scientific operates Vercise deep brain stimulation systems and acquired Axonics in 2024 to enter sacral neuromodulation, making it a broad incumbent in implantable neurostim with overlapping commercial channels and an active acquirer in the space (Mobia's leadership has multiple Boston Scientific alumni).

Others

  • Penumbra: Penumbra is a neurovascular company whose stroke-thrombectomy franchise (and Lightning/Indigo product lines) is sold into the same US comprehensive stroke centers that are Mobia's Vivistim customers; it is not a direct competitor in chronic stroke recovery but shares the call point and is a relevant comp for stroke-care medtech economics.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Mobia Medical social profiles

Digital presence

Mobia Medical compliance and trust

Trust signal

Compliance6 records

Mobia Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mobia Medical leadership team

Management profile

Number of profiles

Profiles14 records

Mobia Medical funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mobia Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mobia Medical

What does Mobia Medical do?

Mobia Medical develops and commercializes the Vivistim® Paired VNS™ System, an FDA-approved implantable neurostimulation device that delivers targeted vagus nerve stimulation paired with rehabilitation therapy to promote neuroplasticity and improve upper extremity motor function in chronic ischemic stroke survivors with moderate to severe arm impairment. The company sells the device plus associated clinical support services to US stroke centers, therapy clinics, and implanting physicians, reimbursed primarily through Medicare and commercial insurance.

Is Mobia Medical a public or private company?

Mobia Medical is a public company. It is classified as public and is currently ipo.

When was Mobia Medical founded?

Mobia Medical was founded in 2007. It employs 51 to 100 people.

Where is Mobia Medical based?

Mobia Medical is headquartered in Austin, United States, in the North America region.

How does Mobia Medical make money?

One revenue line is on record: vivistim System Hardware Sales.

Who are Mobia Medical's main competitors?

Direct peers on record are Inspire Medical Systems, Axonics, LivaNova, CVRx and Nevro. ElectroCore is listed as an emerging player. Broad incumbents are Medtronic, Abbott and Boston Scientific. Penumbra is listed as an others.

Does Mobia Medical have an API?

No public API is recorded for Mobia Medical.

What industry is Mobia Medical in?

Mobia Medical's product category is Neurostimulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAKAIAG, Stroke & Vascular Neurology. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaMobia Medical, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:MOBI) 2026-11-06Mobia Medical reported Q3 2026 EPS of -$0.52, missing by $0.06, while revenue of $15.62M beat by $1.58M. The company's stock closed at $11.12, down 1.42%.Investing.comBTIG raises Mobia Medical stock price target to $20 on resultsBTIG raised its price target on Mobia Medical to $20 from $19, keeping a Buy rating. The firm cited Q3 2026 revenue of $15.6 million, up 73.3% year-over-year, and raised fiscal 2026 revenue guidance to $57.0–57.5 million. The company also reported a $0.52 loss per share.TradingViewMobia Medical Q3 2026 Earnings Call Is LiveMobia Medical's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. Management commentary on demand, margins, or capital spending may move markets.MarketBeatMobia Medical, Inc. (NASDAQ:MOBI) Stock Has Consensus Price Target of $20.75 According to AnalystsAnalysts rate Mobia Medical a Moderate Buy with an average price target of $20.75. Director Casey Tansey bought 35,572 shares at $11.51, and the company reported Q2 EPS of -$1.10, missing the -$0.83 consensus, though revenue rose 102.4% year-over-year.American Banking and Market NewsMobia Medical, Inc.’s Lock-Up Period Will Expire on November 4th (NASDAQ:MOBI)Mobia Medical's lock-up period ends November 4th, allowing insiders and major shareholders to sell shares. Analysts have a consensus target price of $20.75, with an average rating of Moderate Buy. The company reported a loss of $1.10 per share for the quarter, missing estimates.American Banking and Market NewsMobia Medical’s (MOBI) Buy Rating Reaffirmed at BTIG ResearchBTIG Research reaffirmed a buy rating on Mobia Medical with a $19 target, implying 79.58% upside. The stock rose 9.8% to $10.58, while the company reported a loss of $1.10 EPS, missing estimates. Analysts' consensus is a Moderate Buy with an average target of $20.75.American Banking and Market NewsMobia Medical (NASDAQ:MOBI) Given Buy Rating at BTIG ResearchBTIG Research reaffirmed a buy rating on Mobia Medical with a $19 target, implying 92.5% upside from current price. The stock rose 2.4% to $9.87, while the company reported a loss of $1.10 per share, missing estimates. Analysts average a Moderate Buy rating with a $20.75 target.American Banking and Market NewsMobia Medical (NASDAQ:MOBI) Stock Keeps Buy Rating at BTIG ResearchBTIG Research reaffirmed a buy rating on Mobia Medical with a $19 price target, implying 94.67% upside. The stock rose 1.2% to $9.76, while the company reported Q2 EPS of -$1.10, missing estimates. Analysts forecast a -2.63 EPS for the current fiscal year.American Banking and Market NewsMobia Medical (NASDAQ:MOBI) Stock Rating Reaffirmed as “Buy” by BTIG ResearchBTIG Research reaffirmed a Buy rating on Mobia Medical with a $19 price target, implying 97.10% upside. The company reported Q2 EPS of -$1.10, missing estimates, but revenue rose 102.4% year-over-year. Director Casey Tansey bought 35,572 shares, and institutional investors added stakes.American Banking and Market NewsMobia Medical (NASDAQ:MOBI) Earns Buy Rating from BTIG ResearchBTIG Research restated a buy rating on Mobia Medical with a $19 price target, implying 97.10% upside. The company reported Q2 EPS of -$1.10, missing the -$0.83 consensus, while revenue rose 102.4% year-over-year. Analysts' consensus is a Moderate Buy with a $20.75 target.